Literature DB >> 8580904

Adrenal changes in murine pulmonary tuberculosis; a clue to pathogenesis?

R Hernandez-Pando1, H Orozco, J Honour, P Silva, R Leyva, G A Rook.   

Abstract

When mice were infected with virulent Mycobacterium tuberculosis H37Rv by the intra-tracheal route, there was an early phase of adrenal hyperplasia, histologically resembling the adrenocorticotropic (ACTH)-driven changes seen in Cushing's disease. This was followed at 3 weeks by progressive atrophy until the weight of the adrenals was approximately 50% of that seen in control uninfected mice, in spite of the fact that the adrenals were not infected. All layers of the adrenal cortex were affected, but the medulla was normal. Electron microscope studies revealed apoptosis. The switch from adrenal hyperplasia to adrenal atrophy corresponded to onset of an IgG1 response recognising a wide range of mycobacterial components in Western blots. Delayed type hypersensitivity (DTH) responses were seen throughout, but differed in their sensitivity to TNF alpha. Thus if TNF alpha was injected at 24 h into DTH sites elicited during the phase of adrenal hyperplasia, there was no increment in swelling at 48 h. However similar injections of TNF alpha resulted in a doubling of the swelling in DTH sites elicited during the phase of adrenal atrophy. This may be relevant to the pathogenesis of cytokine-mediated tissue damage in the human disease. If 2 months before mice received the intratracheal infection, they were pre-immunised with 1 x 1097) autoclaved Mycobacterium vaccae, a stimulus previously shown to induce a Th1 pattern of response, the early increase in adrenal weight was attenuated and delayed, and the subsequent atrophy did not occur. In sharp contrast, pre-immunisation with 1 x 10(9) autoclaved M. vaccae, known to prime a mixed pattern of cytokine release (IFN gamma and IL-4), resulted in adrenal atrophy that began within 4 days of infection, and was complete by day 14. These results suggested that the pattern of cytokine release provoked by the infection, modulated the adrenal changes, perhaps in synergy with products derived from the organisms themselves. Since we have already shown that profound adrenal changes also occur in human tuberculosis, we now propose that a change somewhere in the cytokine-hypothalamo-pituitary-adrenal axis may underlie the T cell dysfunction and immunologically-mediated tissue damage in this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580904     DOI: 10.1111/j.1574-695X.1995.tb00176.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  14 in total

1.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function.

Authors:  F Kelestimur
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

3.  Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection.

Authors:  R Hernandez-Pando; L Pavön; K Arriaga; H Orozco; V Madrid-Marina; G Rook
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice.

Authors:  R Hernandez-Pando; H Orozco; K Arriaga; L Pavön; G Rook
Journal:  Int J Exp Pathol       Date:  2000-06       Impact factor: 1.925

5.  Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in BALB/c mice.

Authors:  R Hernandez-Pando; L Pavon; E H Orozco; J Rangel; G A Rook
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

6.  Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis.

Authors:  R A Fabre; T M Pérez; L D Aguilar; M J Rangel; I Estrada-Garcìa; R Hernández-Pando; S Estrada Parra
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

7.  In situ analysis of lung antigen-presenting cells during murine pulmonary infection with virulent Mycobacterium tuberculosis.

Authors:  Alexander Pedroza-González; Gina S García-Romo; Diana Aguilar-León; Juana Calderon-Amador; Raquel Hurtado-Ortiz; Hector Orozco-Estevez; Bart N Lambrecht; Iris Estrada-García; Rogelio Hernández-Pando; Leopoldo Flores-Romo
Journal:  Int J Exp Pathol       Date:  2004-06       Impact factor: 1.925

8.  Airways infection with virulent Mycobacterium tuberculosis delays the influx of dendritic cells and the expression of costimulatory molecules in mediastinal lymph nodes.

Authors:  Gina S García-Romo; Alexander Pedroza-González; Diana Aguilar-León; Hector Orozco-Estevez; Bart N Lambrecht; Iris Estrada-Garcia; Leopoldo Flores-Romo; Rogelio Hernández-Pando
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

9.  Multigenic control of disease severity after virulent Mycobacterium tuberculosis infection in mice.

Authors:  Fabio Sánchez; Tatiana V Radaeva; Boris V Nikonenko; Ann-Sophie Persson; Selim Sengul; Martin Schalling; Erwin Schurr; Alexander S Apt; Catharina Lavebratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  16α-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis co-morbidity treatment.

Authors:  Manuel Othoniel López-Torres; Brenda Marquina-Castillo; Octavio Ramos-Espinosa; Dulce Mata-Espinosa; Jorge A Barrios-Payan; Guillermina Baay-Guzman; Sara Huerta Yepez; Estela Bini; Ivan Torre-Villalvazo; Nimbe Torres; Armando Tovar; William Chamberlin; Yu Ge; Andrea Carranza; Rogelio Hernández-Pando
Journal:  Clin Exp Immunol       Date:  2021-06-01       Impact factor: 5.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.